Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of Venetoclax and BEAM Conditioning Followed by Autologous Stem Cell Transplantation for Patients With Primary Refractory Non-Hodgkin Lymphoma

NCT03583424 is registered in ClinicalTrials.gov with Ohio State University Comprehensive Cancer Center as lead sponsor.

NCT NCT03583424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03583424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of Venetoclax and BEAM Conditioning Followed by Autologous Stem Cell Transplantation for Patients With Primary Refractory Non-Hodgkin Lymphoma
Lead sponsor
Ohio State University Comprehensive Cancer Center
Phase
Phase 1/2
Overall status
Completed
Start date
September 10, 2018
Completion date
September 30, 2021
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic cell transplantation recipient, recurrent diffuse large b-cell lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent marginal zone lymphoma, recurrent non-hodgkin lymphoma, refractory diffuse large b-cell lymphoma, refractory follicular lymphoma, refractory marginal zone lymphoma, refractory non-hodgkin lymphoma, refractory transformed indolent non-hodgkin lymphoma